Home
  Links
 
  Log in

 
Software to download.

Publications        Conference Presentations        UK CHIC presentation



  Publications                                                                                                                     Back to top
  2016

  Development and application of a new measure of engagement in out-patient HIV care.
Howarth AR, Burns FM, Apea V, Jose S, Hill T, Delpech VC, Evans A, Mercer CH, Michie S, Morris S, Sachikonye M, Sabin C; REACH study; UK Collaborative HIV Cohort (UK CHIC) study.
HIV Med 2016; [Epub ahead of print].

  Predicting virological decay in patients starting combination antiretroviral therapy.
UK Collaborative HIV Cohort (UK CHIC) Writing Committee.
AIDS 2016; 30:1817-27. PubMed link

  Can hepatitis C Virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights.
Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, Martin TC, Delpech V, Ruf M, Price H, Azad Y, Thomson EC, Vickerman P.
Clin Infect Dis 2016; 62:1072-80. PubMed link

  Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.
Booth JW, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar EA, Turner-Stokes T, Khatib N, Das P, Naftalin C, Mackie N, Kingdon E, Williams D, Hendry BM, Sabin C, Jones R, Levy J, Hilton R, Connolly J, Post FA; HIV/CKD Study and the UK CHIC Study.
Nephrol Dial Transplant 2016 [Epub ahead of print]

  Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.
Jose S, Quinn K, Dunn D, Cox A, Sabin S, Fidler S; UK CHIC and UK HDRD Steering Committees.
HIV Med 2016; 17:368-72. [PubMed link]

  No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom.
White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin c, Pillay D, Dun DT; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.
J Infect Dis 2016 [Epub ahead of print]

  Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.
De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Gunthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schulter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord.
J Antimicrob Chemother 2016; 71:1352-60. PubMed link

  Chronic hepatitis B and C virus infection and risk for non-Hodgkin lymphoma in HIV-infected patients: a cohort study.
Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, Smit C, Schommers P, Thornton A, Berenquer J, Peters L, Spagnuolo V, Ammassari A, Antinori A, Roldan EQ, Mussini C, Miro JM, Konopnicki D, Fehr J, Campbell MA, Termote M, Bucher HC; Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
Ann Intern Med 2016 Oct 18 doi: 10.7326/M16-0240. [Epub ahead of print]

  Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.
Antiretroviral Therapy Cohort Collaboration (ART-CC); Canadian Observational Cohort Collaboration (CANOC); UK Collaborative HIV Cohort Study (UK CHIC); Collaboration of Observational HIV Epidemiological Research in Europe COHERE).
AIDS 2016; 30:503-13. PubMed link

  Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment naïve patients.
Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, d'Arminio Monforte A, Mary-Krause M, Roca B, Miro JM, Battegay M, Brockmeyer N, Berenguer J, Mirlat P, Obel N, De Wit S, Fätkenheuer G, Zangerle R, Ghosn J, Pérez-Hoyos S, Campbell M, Prins M, Chêne G, Meyer L, Dorrucci M, Torti C, Thiébaut R; Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
HIV Med 2016 Sept 14. doi: 10.1111/hiv.12389. [Epub ahead of print]

  2015

  Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.
Winston A, Jose S, Fisher M, Walsh J, Nelson M, Gilson R, Post F, Johnson M, Leen C, Chadwick D, Hay P, Pritchard J, Tariq A, Sabin C; UK Collaborative HIV Cohort Study.
J Allergy Clin Immunol 2015; 136:1682-5. [PubMed link].

  Renal tubular disease in the era of combination antiretroviral therapy.
Hamzah L, Booth JW, McAdoo SP, Kumar EA, O'Donnell P, Hilton R, Sabin C, Williams DI, Jones R, Post FA; HIVCKD Study.
AIDS 2015; 29:1831-6. PubMed link

 

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy.
Huntington S, Thorne C, Newell M-L, Anderson J, Taylor GP, Pillay D, Hill T, Tookey P, Sabin C; on behalf of the UK Collaborative HIV Cohort (UK CHIC) Study and the UK and Ireland National Study of HIV in Pregnancy and Childhood.
AIDS 2015; 29:2269-78. PubMed link

  Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.
Huntington S, Thorne C, Newell ML, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA,
Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study and the UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC).
AIDS 2015; 29:801-9. PubMed Link

  A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.
Mourad R, Chevennet F, Dunn DT, Fearnhill E, Delpech V, Asboe D, Gascuel O, Hue S; UK HIV Drug Resistance Database & the Collaborative HIV, Anti-HIV Drug Resistance Network.
AIDS 2015; 29:1917-25. PubMed link

  Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
Late presenters working froup in COHERE in EuroCoord., Mocroft A, Lundgren J, Antinori A, Monforte Ad, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chêne G, Raben D, Kirk O.
Euro Surveill 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30070. PubMed link

  2014

  End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study.
Gathogo E, Jose S, Jones R, Levy JB, Mackie NE Booth J, Connolly J, Johnson M, Leen C, Williams D, Sabin CA, Post FA.
J Acquir Immune Defic Syndr 2014; 67:177-80. PubMed Link

  Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Jose S, Hamzah L, Campbell, LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P, Johnson M, Chadwick D, Nitsch D, Jones R, Sabin CA, Post FA; UK Collaborative HIV Cohort Study Steering Committee.
J Infect Dis 2014; 210:363-73. PubMed Link

  Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.
Jose S, Quinn K, Hill T, Leen C, Walsh J, Hay P, Fisher M, Post F, Nelson M, Gompels M, Johnson M, Chadwick D, Gilson R, Sabin C, Fidler S; UK CHIC Steering Committee.
AIDS 2014; 28:1333-9. PubMed Link

  The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations.
Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C, Gompels M, Gilson R, Post FA, Hay P, Sabin CA; UK Collaborative HIV Cohort Study.
HIV Med 2014; 15:311-6. PubMed link

  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Bulteel N, Bansi-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Sabin C, Nelson M; UK Collaborative HIV Cohort (CHIC) Study Group; UK HIV Drug Resistance Database (UK HDRD) Study Group.
J Infect 2014; 68:77-84. PubMed link

  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK
May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C; for the UK Collaborative HIV Cohort (UK CHIC) Study.
AIDS 2014; 28:1193-202. PubMed Link

  Failure to achive a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R, Mackie N, Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman A, Post F, Johnson M, Sabin CA, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Steering Committee.
AIDS 2014; 28:919-24. PubMed link

  Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women.
Huntington S, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey P,
Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study,; National Study of HIV in Pregnancy and Childhood (NSHPC).
BMC Infect Dis 2014; 14:127. PubMed link

  The contribution of viral genotype to plasma viral set-point in HIV infection.
Hodcroft E, Hadfield JD, Fearnhill E, Phillips A, Dunn D, O'Shea S, Pillay D, Leigh Brown AJ; UK HIV Drug Resistance Database and the UK CHIC Study.
PLoS Pathog. 2014 May 1;10(5):e1004112. PubMed link

  Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.
Engsig FN, Zangerle R, Katsarou, O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fatkenheuer G, Gutierrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
Clin Infect Dis 2014; 58:1312-21. PubMed link

  Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals.
Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
AIDS 2014; 28:1351-6. PubMed link

  2013

  HLA B*5701 status, disease progression, and response to antiretroviral therapy.
UK Collaborative HIV Cohort Study Steering Committee.
AIDS 2013; 27:2587-92. PubMed link

  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.
Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA; on behalf of the UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort Study (UK CHIC).
J Antimicrob Chemother 2013; 68:2339-43. PubMed link

  Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.
Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C; on behalf of the UK Collaborative HIV Cohort Study.
J Antimicrob Chemother 2013; 68:1354-9. PubMed link

  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected adults.
Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM; UK HIV Drug Resistance Database, UK CHIC Study.
AIDS 2013; 27:2245-53. PubMed link

  Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.
Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A, UK CHIC Study; UK HIV Drug Resistance Database.
Antivir Ther 2013; 18:213-9. PubMed link

  Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care.
Huntington SE, Thorne C, Bansi LK, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC).
AIDS 2013; 27:95-103. PubMed link

  HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis.
Dolling DI, Dunn DT, Geretti AM, Sabin CA; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.
Clin Infect Dis 2013; 56:162-3. PubMed link

  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.
HIV Med 2013; 14:571-7. PubMed link

  Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.
Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Costagliola D, Ledergerber B, van Sighem A, Podzamczer D, Mocroft A, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fatkenheuer G, Touloumi G, Mussini C, Stephan C, Garcia F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup K, Phillips A, Lodwick R, Torti C, Dorrucci M, Gunthard HF, Michalik C, Chrysos G, Castagna A.
J Infect Dis 2013; 207:759-67. PubMed link

  Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Leport C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Kirk O,; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.
PLoS Med. 2013;10(9):e1001510. doi: 10.1371/journal.pmed.1001510. PubMed link

  The incidence of AIDS-defining illnesses at a current CD4 count > 200cells/µL in the post- combination antiretroviral therapy era.
Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Lundgren JD; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.
Clin Infect Dis 2013: 57:1038-47. PubMed link

  2012

  Hepatitis B virus infection in HIV-positive individuals in the UK Collaborative HIV Cohort (UK CHIC) Study.
Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M, Pillay D, Rodger A, Taylor C, Gilson R, UK Collaborative HIV Cohort Hepatitis Group, Steering Committee.
PLoS One Epub 2012 Nov 7. PubMed link

  Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women.
Huntington SE, Bansi LK, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) STudy and National Study of HIV in Pregnancy and Childhood (NSHPC).
BMC Med Res Methodol 2012; 12:110. PubMed link

  Non-uptake of highly active antiretroviral therapy among patients with a CD4 count <350 cells/uL in the UK.
Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA; UK Collaboartive HIV Cohort (CHIC) Study.
HIV Med Epub 2011 Nov 22. PubMed link

  Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?
Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T, Johnson M, Gilson R, Bansi L, Easterbrook P, Fisher M, Walsh J, Orkin C, Ainsworth J, Leen C, Sabin C; UK Collaborative HIV Cohort (UK CHIC) study.
J Infect Dis 2012; 205:540-7. PubMed link

  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.
Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; UK HIV Drug Resistance Database and UK Collaborative HIV cohort (UK CHIC) Study Steering Committees.
J Antimicrob Chemother 2012; 67:995-1000. PubMed link

  Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients.
Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA; UK Collaborative HIV Cohort (CHIC)/CKD Study Group.
Am J Kidney Dis 2012; 60:539-47. PubMed link

  Uptake and outcome of combination antiretroviral therapy in men who have sex with men according to ethnic group: the UK CHIC Study.
United Kingdom Collaborative HIV Cohort Study Group.
J Acquir Immune Defic Syndr 2012; 59:523-9. PubMed link

  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
Dolling D, Phillips AN, Delpech V, Pillay D, Cane PA, Crook AM, Shepherd J, Fearnhill E, Hill T, Dunn D; UK HIV Drug Resistance Database; UK Collaborative HIV Cohort (UK CHIC) Study.
HIV Med 2012; 13:309-14. PubMed link

  Biomarkers to monitor safety in people on ART and risk of mortality.
Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M, Sabin C; UK Collaborative Cohort Study.
J Acquir Immune Defic Syndr 2012; 60:51-8. PubMed link

  Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients.
Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA; UK CHIC/CKD* Study Group.
Nephrol Dial Transplant 2012; 27:2291-7. PubMed link

  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sonnerborg A, Codoner FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain.
J Infect Dis 2013; 207:1216-20. PubMed link

  All cause mortality in treated HIV-infected adults with CD4>500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
Collaboartion of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord., Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G.
Int J Epidemiol 2012; 41:433-45. PubMed link

  CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
Opportunistic Infections Team of the Collaboration for Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord., Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer H, Castagna A, De Wit S, Muñoz J, Kjaer J, Grarup J, Chêne G, Bucher H.
PLoS Med 2012;9(3):e1001194. doi: 10.1371.journal.pmed.1001194. PubMed link

  Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
Pursuing Later Treatment Options II (PLATO II) project team.; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group., Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, Garcia F, De Wit S, Stephan C, Obel N, Fätkenhaeuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre Colin C, Kjaer J, Chêne G, Grarup J, Phillips A.
J Acquir Immune Defic Syndr 2012; 59:294-9. PubMed link

  Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
Pursuing Later Treatment Options II (PLATO II) project team.; Observational HIV Epidemiological Research Europe (COHERE) Group., Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenhaeuer G, Touloumi G, Mussini C, Castagna A, Stephan C, Garcia F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A.
Lancet Infect Dis 2012; 12:119-27. PubMed link
  2011

  Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.
May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C.
BMJ 2011 Oct 11;343:d6016. PubMed link

  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.
Cozzi-Lepri A, Prosperi MC, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D; EuroSIDA STudy; United Kingdom CHIC; United Kingdom HDRD Study.
PLoS One 2011;6(11):e25665. PubMed link

  Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.
Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA; UK CHIC Study Steering Committee.
Antivir Ther 2011; 16:805-14. PubMed link

  Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.
Huntington SE, Bansi LK, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin C; on behalf of the UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC).
AIDS 2011; 25:1647-55. PubMed link

  Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV cohort (CHIC) Study.
Hughes R, Sterne J, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J, Anderson J, Gompels M, Dunn D, Johnson M, Phillips A, Pillay D, Leen C, Easterbrook P, Gazard B, Fisher M, Sabin C.
HIV Med 2011; 12:583-93. PubMed link

  Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C; for the UK CHIC Steering Committee.
HIV Med 2011; 12:289-298. PubMed link

  The impact of HIV drug resistance testing on changes to treatment.
Bansi L, Smith C, Phillips A, Kirk S, Geretti AM, Johnson M, Mackie N, Post F, Gazzard B, Dunn D, Sabin C; UK Collaborative HIV Cohort (CHIC) Study and the UK Collaborative Group on HIV Drug Resistance (HDRD).
AIDS 2011; 25:603-10. PubMed link

  HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.
UK Collaborative HIV cohort (CHIC) Study Steering Committee, Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Phillips AN, Sabin CA.
Eur J Neurol 2011; 18:527-34. PubMed link

  Antiretroviral therapy CNS penetration and HIV-1 associated CNS disease.
Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen, C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C , Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA; UK Collaborative HIV Cohort (CHIC) study.
Neurology 2011; 76:693-700. PubMed link

 

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.
Ann Intern Med 2011; 154:509-15. PubMed link

  2010

  Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.
Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M, Porter K, Anderson J, Gompels M, Leen C, Ainsworth J, Orkin C, Nelson M, Rice B, Phillips A; UK Collaborative HIV Cohort (CHIC) Study and the Health Protection Agency.
HIV Med 2010; 11:432-8. PubMed link

  The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes.
Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study.
J Viral Hepat 2010; 17:569-77. PubMed link

  Data linkage reduces loss to follow-up in an observational HIV cohort study.
Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M, Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker A, Delpech V; UK Collaborative HIV Cohort Study Group.
J Clin Epidemiol 2010; 63:1101-9. PubMed link

  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D; UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study (UK CHIC).
AIDS 2010; 24:1917-22. PubMed link

  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.
UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group.
Clin Infect Dis 2010; 50:1275-85. PubMed link

  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART).
Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A, Sabin C; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort (CHIC) Study.
J Acquir Immune Defic Syndr 2010; 53:633-9. PubMed link

  Antiretroviral drug resistance in HIV-1-infected patients with low-level viraemia.
Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM.
J Infect Dis 2010; 201:1303-7. PubMed link

  Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK.
Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S; UK Collaborative Group on HIV Drug Resistance.
AIDS 2010; 24:2397-401. PubMed link

  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B, Pillay D, Dunn DT; UK Collaborative Group on HIV Drug Resistance.
Antivir Ther 2010; 15:985-91. PubMed link

  Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study.
Antivir Ther 2010; 15:203-11. PubMed link

  Late diagnosis in the HAART era: proposed common definitions and associations with mortality.
UK Collaborative HIV Cohort (UK CHIC) Steering committee, Sabin CA, Schwenk A, Johnson MA, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T, Gilson R, Porter K, Easterbrook P, Delpech V, Bansi L, Leen C, Gompels M, Anderson J, Phillips AN.
AIDS 2010; 24:723-7. PubMed link

  Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort Study (UK CHIC).
Gilson R, Man S-L, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C, Pillay D, Schwenk A, Johnson M, Easterbrook P, Walsh J, Fisher M, Anderson J, Leen C, Sabin CA; UK Collaborative HIV Cohort Study Group.
HIV Med 2010; 11:152-60. PubMed link

  Factors influencing lopinavir and atazanavir plasma concentration.
Stöhr W, Back D, Dunn D, Sabin C, Wilson A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, UK CHIC Steering Committee.
J Antimicrob Chemother 2010; 65:129-37. PubMed link

  Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Study group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobsen L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Kelin MB, Gange S, Riera M, Mussini C, Gutierrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN.
Lancet 2010; 376(9738):340-5. PubMed link

  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.
HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Perez-Hoyos S, Garcia de Olalla P, Hernan MA.
AIDS 2010: 24:123-37. PubMed link

  Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, Garcia F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warsawski J, Thorne C, Masip J, Perez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Gunthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chene G, Lundgren JD, Phillips AN.
Arch Intern Med 2010; 170:410-9. PubMed link

  2009

  Clinical epidemiology of HIV-associated end-stage renal failure in the UK.
Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, Edwards S, Connolly J, Holt SG, Hendry BM, Sabin C, Post FA; UK CHIC/ESRF study group.
AIDS 2009; 23:2517-21. PubMed link

  Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?
Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M, Hill T, Johnson M, Leen C, Orkin C, Phillips AN, Porter K, Post F, Walsh J, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group.
AIDS 2009; 23:2507-15. PubMed link

 

Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Stöhr W, Back D, Dunn D, Sabin C, Wilson A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi R, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; Liverpool TDM Database; UK CHIC Study.
Antivir Ther 2008; 13:675-85. PubMed link

  Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK Collaborative HIV Cohort Study.
J Infect Dis 2009; 200:710-4. PubMed link

  The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.
Sabin CA, Smith CS, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study.
HIV Med 2009; 10:35-43. PubMed link

  CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.
Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA; UK CHIC Steering Committee.
Haematologica 2009; 94:875-80. PubMed link

  Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Wilson A, Orkin C, Easterbrook P, Phillips A, Sabin C; on behalf of the UK Collaborative HIV Cohort (CHIC) Study.
J Acquir Immune Defic Syndr 2009 Epub ahead of print PubMed link

  Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration.
AIDS 2009; 23:1689-99. PubMed link

  Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M.
Antivir Ther 2009; 14:1065-74. PubMed link

  Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group, Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Toulomi G, Miro JM, Chene G, Lundgren J, Egger M.
AIDS 2009; 23:2029-37. PubMed link

  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance.
Clin Infect Dis 20090; 48:1296-305. PubMed link

  2008

  Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.
United Kingdom Collaborative HIV Cohort Study, Lee KJ, Dunn D, Gilson R, Porter K,
Bansi L, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C.
AIDS 2008; 22:1943-50. PubMed link

  Patterns and predictors of the use of different antiretroviral drug regimes at treatment initiation in the UK.
Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, and Sabin CA; on behalf of the UK Collaborative HIV Cohort (CHIC) Study Steering Committee.
HIV Medicine 2008; 9:47-56. PubMed link

  Are prior treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study.
AIDS 2008; 22:349-56. PubMed link

  Changes in outcome of persons initiating HAART at CD4 less than 50 cells/mm3.
K Porter, S Walker, T Hill, J Anderson, C Leen, M Johnson, B Gazzard, J Walsh, M Fisher, C Orkin, A Schwenk, R Gilson, P Easterbrook, V Delpech, CA Sabin; on behalf of the UK CHIC Study Group.
J Aquir Immune Defic Syndr 2008; 47:202-205. PubMed link

  Response to combination antiretroviral therapy: variation by age.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiget M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J.
AIDS 2008; 22:1463-73. PubMed link

  Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.
Dunn D, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C, Phillips A; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study.
Antivir Ther 2008; 13:771-7. PubMed link

  What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?
Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin C, Phillips A, Allen E, Pillay D; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study (UK CHIC).
J Antimicrobial Chemother 2008; 61:705-13. PubMed link

  2007

 

Risk of extensive virologic failure to the three original antiretroviral drug classes over long term follow-up from the start of therapy among patients with HIV infection: an observational cohort study.
Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study.
Lancet 2007; 370:1923-8. PubMed link

  HIV diagnosis at CD4 count above 500/mm3 and progression to below 350/mm3 without antiretroviral therapy.
UK Collaborative HIV Cohort (CHIC) Study Steering Committee.
J Acquir Immune Defic Syndr 2007; 46:275-8. PubMed link

  Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
The UK Collaborative HIV Cohort (CHIC) Study Steering Committee.
(Analysis and writing committee/UK CHIC steering committee: Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A; UK Collaborative HIV Cohort Study.)
AIDS 2007; 21:1717-1721. PubMed link

  Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.
Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Dunn D, Delpech V, Taylor GP, Walsh JC, Phillips AN on behalf of the UK Collaborative HIV Cohort (CHIC) Study.
AIDS 2007; 21:1423-1430. PubMed link

  CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.
Stöhr W, Dunn DT, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson MA, Delpech VC, Phillips AN and Sabin CA, on behalf of the UK CHIC Study.
HIV Medicine 2007; 8(3): 135-141. PubMed link

  Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom.
UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study; UK Register of HIV Seroconverters.
AIDS 2007; 21:1035-9. PubMed link

  Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy.
Nebbia G, Sabin CA, Dunn DT, Geretti AM; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort (CHIC) Study Group.
J Antimicrob Chemother 2007; 59:1013-6. PubMed link

  2005

  The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study.
Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Scullard G, Matthias R, Johnson MA, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group.
J Infect Dis. 2005 Oct;192(8):1387-97 PubMed link

  Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Group.
BML 2005 Mar 330(7493):695 PubMed link

  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group.
AIDS 2005; 19:487-94. PubMed link

  2004

  The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study.
The UK Collaborative HIV Cohort Steering Committee.
HIV Med. 2004 Mar;5(2):115-24 PubMed link

   
  Conference Presentations                                                                              Back to top
  2015

  Outcomes after two years on antiretroviral therapy (ART): comparison of women who were ART-naive and women who previously used short-course ART in pregnancy.
S Huntington, C Thorne, J Anderson, ML Newell, GP Taylor, D Pillay, T Hill, P Tookey, C Sabin, for UK CHIC and the NSHPC.
15th European AIDS Conference, 2015. Abstract/Oral PS6/4.
  Using the Programmatic Compliance Score (PCS) to estimate initial HIV care among HIV-positive individuals starting antiretroviral therapy in the United Kingdom and Canada.
J Raboud on behalf of Canadian Observational Cohort (CANOC) and UK Collaborative Cohort (CHIC) Study.
19th International Workshop on HIV Observational databases, 2015.

  The effect of duration of previously untreated HIV infection on CD4:CD8 ratio recovery after initiation of antiretroviral therapy.
S Jose, A Winston, K Porter, C Sabin.
19th International Workshop on HIV Observational databases, 2015.

  Development of a new measure to characterise retention in outpatient HIV care.
A Howarth, F Burns, V Apea, S Jose, T Hill, C Sabin.
19th International Workshop on HIV Observational databases, 2015.

  Investigating associations between a dynamic measure of retention-in-care (RIC) and clinical outcomes in the presence of time-varying confounding and reverse causality.
C Sabin, A Howarth, S Jose, T Hill, V Apea, F Burns on behalf of UK CHIC.
19th International Workshop on HIV Observational databases, 2015.

  Investigating associations betwen a new measure of engagement in-care and clinical outcomes in the UK Collaboartive HIV Cohort (UK CHIC) study.
C Sabin, A Howarth, S Jose, T Hill, F Burns, V Apea.
21st Annual Conference of the British HIV Association (BHIVA), 2015, Oral 2.
HIV Medicine 2015; 16 (Suppl. 2), 12-77.

  Treatment for hepatitis C infection in the UK Collaborative HIV Cohort (UK CHIC) study.
A Rodger, A Thornton, C Sabin, S Jose, D Dunn, R Gilson, S Bhagani, D Chadwick, M Fisher, J Main, C Taylor, M Nelson.
21st Annual Conference of the British HIV Association (BHIVA), 2015, Oral 20.
HIV Medicine 2015; 16 (Suppl. 2), 12-77.

  Initiation of anti-retrovirals in HIV/HCV-coinfected MSM: Are we too late?
T Martin, M Nelson, S Jose, A Thornton, C Sabin, N Martin M Hickman.
21st Annual Conference of the British HIV Association (BHIVA), 2015, Oral 22.
HIV Medicine 2015; 16 (Suppl. 2), 12-77.

  Hepatitis B treatment strategies and virological outcomes in the UK Collaborative HIV Cohort (UK CHIC) study.
A Thornton, C Sabin, S Jose, A Rodger, D Dunn, R Gilson, S Bhagani, D Chadwick, M Fisher, J Main, M Nelson, C Taylor.
21st Annual Conference of the British HIV Association (BHIVA), 2015, Poster 65.
HIV Medicine 2015; 16 (Suppl. 2), 12-77.

  Development of a new measure to characterise engagement in outpatient HIV care.
A Howarth, F Burns, S Jose, T Hill, C Sabin, V Apea.
21st Annual Conference of the British HIV Association (BHIVA), 2015, Poster 171.
HIV Medicine 2015; 16 (Suppl. 2), 12-77.

  2014

  Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure.
A Schultze, R Paredes, C Sabin, AN Phillips, D Pillay, O Kirk, JD Lundgren, A Pozniak, M Nelson, A Cozzi-Lepri, on behalf of Eurosida in Eurocoord.
International Congress of Drug Therapy in HIV Infection, 2014.
J Int AIDS Soc 2014, 17(Suppl. 3):19737

  Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study.
J O'Connor, C Smith, F Lampe, M Johnson, C Sabin, A Phillips.
International Congress of Drug Therapy in HIV Infection, 2014.
J Int AIDS Soc 2014, 17(Suppl. 3):19527.

  Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018.
A Hill, T Hill, S Jose, A Pozniak.
International Congress of Drug Therapy in HIV Infection, 2014.
J Int AIDS Soc 2014, 17(Suppl. 3):19497.

  Does pregnancy incrase the risk of ART-induced hepatotoxicity among HIV-positive women?
S Huntington,C Thorne, J Anderson, ML Newell, G Taylor, D Pillay, T Hill, P Tookey, C Sabin.
International Congress of Drug Therapy in HIV Infection, 2014.
J Int AIDS Soc 2014, 17(Suppl. 3):19486.

  End-stage kidney disease and kidney transplantation in HIV-positive patients in the UK Collaborative HIV Cohort (CHIC) study.
S Jose, E Gathogo, J Booth, S McAdoo, E Kumar, M Rayment, C Leen, D Williams, F Post and C Sabin.
Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), 2014. Oral 25.
HIV Medicine 2014; 15 (Suppl. 3), 1-16.

  Factors associated with interfals between visits to HIV outpatient clinics.
A Evans, C Sabin, V Apea, S Jose, T Hill and F Burns.
Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), 2014. Poster 1.
HIV Medicine 2014; 15 (Suppl. 3), 17-159.

  Treatment switches following periods of low-level viraemia.
S Jose, E Smit, F Martin, D Dunn, N Mackie, D Churchill and C Sabin.
Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), 2014. Poster 156.
HIV Medicine 2014; 15 (Suppl.3), 17-159.

  Viral hepatitis testing patterns among HIV-positive individuals in the UK Collaborative HIV Cohort (UK CHIC) study.
A Thornton, S Bhagani, A Burroughs, D Chadwick, D Dunn, M Fisher, R Gilson, S Jose, J Main, M Nelson, A Rodger, C Taylor and C Sabin.
Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), 2014. Poster 236.
HIV Medicine 2014; 15 (Suppl. 3), 17-159.

  A comparison of virological outcomes among HIV-positive individuals receiving HAART in Canada and the UK.
S Jose, K Chan, H Samji, A Cescon, T Hill, S Shurgold, A Phillips, R Hogg and C Sabin.
Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), 2014. Poster 325.
HIV Medicine 2014; 15 (Suppl. 3), 17-159.

  Hepatitis B infection among individuals attending for care in the UK Collaborative HIV Cohort (CHIC) Study.
A Thornton, S Bhagani, A Burroughs, D Chadwick, D Dunn, M Fisher, R Gilson, S Jose, J Main, A Rodger, C Sabin, C Taylor and M Nelson.
Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), 2014. Poster 375.
HIV Medicine 2014; 15 (Suppl. 3), 17-159.

  Changes to antiretroviral therapy following periods of low-level viraemia.
S Jose, E Smit, F Martin, D Dunn, NE Mackie, DR Churchill and C Sabin on behalf of the UK CHIC Study Steering Committee.
18th International Workshop on HIV Observational Databases, 2014. Oral 19.

  Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) Study.
J O'Connor, C Smith, F Lampe, C Sabin, and A Phillips on behalf of the UK Collaborative HIV Cohort (UK CHIC) Scientific Steering Committee.
18th International Workshop on HIV Observational Databases, 2014. Poster 71.

  Mortality among ART recipients: a comparison between patients in the United Kingdom and Canada.
S Patterson, H Samji, K Chan, A Cescon, S Jose, S Shurgold, C Sabin and RS Hogg on behalf of the CANOC-UK CHIC Collaboration.
18th International Workshop on HIV Observational Databases, 2014. Poster 114.

  Comparative analysis of late initiation of HIV treatment between Canada and the UK, 2000-2011.
G Colley, A Cescon, H Samji, K Chan, S Jose, S Shrugold, C Sabin and RS Hogg on behalf of the CANOC-UK CHIC Collaboration.
18th International Workshop on HIV Observational Databases, 2014. Poster 121.

  Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens.
V Cambiano, H Castro, D Chadwick, E Smit, AM Geretti, D Dunn, A Phillips, on behalf of UK HIV Drug Resistance Database and UK CHIC study.
Conference on retroviruses and opportunistic infections (CROI) 2014. Poster 593.
[CROI Abstract 593]. Top Antivir Med 2014;22(e-1):291.

  Spectrum of HIV-associated kidney disease in the era of combination antiretroviral therapy.
J Booth, L Hamzah, S Jose, S McAdoo, E Kumar, C Horsfield, P O'Donnell, R Jones, C Sabin, FA Post
Conference on retroviruses and opportunistic infections (CROI) 2014. Poster 793.
[CROI Abstract 793]. Top Antivir Med 2014;22(e-1):407.

  End stage kidney disease and kidney transplantatiojn in HIV-positive patients.
EN Gathogo, S Jose, J Booth, SP McAdoo, EA Kumar, M Rayment, C Leen, D Williams, C Sabin and F Post.
Conference on retroviruses and opportunistic infections (CROI) 2014. Poster 800.
[CROI Abstract 800]. Top Antivir Med 2014;22(e-1):411.

  2013

  The impact of age on associations between HIV-disease markers (immunological and virological) and systemic markers of metabolic function in therapy-naive HIV-infected subjects in the UK Collaborative HIV Cohort (CHIC).
M Samuel, S Jose, A Winston and C Sabin.
19th Annual Conference of the British HIV Association (BHIVA), 2013. Poster 82.
HIV Medicine 2013; 14 (Suppl. 2), 12-77.

  HLA B*5701 positivity, disease status and response to combination antiretroviral therapy (cART) in the UK Collaborative HIV Cohort (CHIC) study.
S Jose, C Sabin, C Leen and D Chadwick for the UK CHIC Study.
19th Annual Conference of the British HIV Association (BHIVA), 2013. Poster 144.
HIV Medicine 2013; 14 (Suppl. 2), 12-77.

  Failure to achieve an adequate CD4 count response despite regular engagement in HIV care and consistent viral suppression.
J O'Connnor, C Smith, F Lampe, M Johnson, C Sabin and A Phillips.
19th Annual Conference of the British HIV Association (BHIVA), 2013. Poster 46.
HIV Medicine 2013; 14 (Suppl. 2), 12-77.

  Associations of retention-in-care (RIC) with calendar year and follow-up time may appear to be incosistent depending on method used to determine RIC.
CA Sabin, G Sethi and J Anderson.
17th International Workshop on HIV Observational Databases,2013. Oral 11.

  Prescribing decisions and virological outcomes follwing a wild-type resistance test result.
D Dolling, M Nelson, A Schwenk, D Churchill, A Pozniak, R Gilson, A Phillips D Pillay and D Dunn on behalf of the UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study.
17th International Workshop on HIV Observational Databases,2013. Poster 43.

  A method for ascertaining hepatitis B virus infection status in HIV cohorts in the presence of missing and/or inconsistent data: An example from the UK CHIC study.
A Thornton, R Gilson and C Sabin.
17th International Workshop on HIV Observational Databases,2013. Poster 89.

  Rapid increase in the frequency of wild type HIV-1 drug resistance reports among ART-experienced patients: UK.
D Dolling, M Nelson, A Schwenk, D Churchill, D Pillay, D Dunn and the UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.
20th Conference on Retroviruses and Opportunistic Infections, 2013. Abstract.

  2012

  The emergence of drug resistant HIV variants at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine within the UK CHIC cohort.
N Bulteel, M Nelson, D Churchill and C Sabin.
18th Annual Conference of the British HIV Association (BHIVA), 2012. Oral O30.
HIV Medicine 2012; 13 (Suppl. 1), 1-11.

  Pregnancies among women seen for HIV-clinical care - predictors and trends over time.
S Huntington, C Thorne, J Anderson, M-L Newell, G Taylor, D Pillay, T Hill, P Tookey and C Sabin.
18th Annual Conference of the British HIV Association (BHIVA), 2012. Poster P76.
HIV Medicine 2012; 13 (Suppl. 1), 86-91. Presentation

  Phylogenetic analysis of HIV transmission among different ethnic MSM groups: UK.
G Sethi, S Edwards, E Fearnhill, D Dunn, V Delpech, C Sabin, A Phillips, D Pillay, A Leigh-Brown, S Hue and the UK HIV Drug Resistance Database and Databases for HIV: Integration, Collaboration & Engagement Project.
19th Conference on Retroviruses and Opportunistic Infections, 2012.

  Using private record linkage to facilitate more accurate cohort analysis.
E Durham, N Lea, T Hill, A Brown, V Delpech and C Sabin.
16th International Workshop on HIV Observational Databases, 2012. Poster 98.

  Patterns of retention and clinical care among HIV-positive men in the UK CHIC Study.
G Sethi, S Edwards, J Anderson, C Sabin, for the UK Collaborative HIV Cohort (CHIC) Study.
11th International Congress on Drug Therapy in HIV Infection, 2012.
Journal of the International AIDS Society 2012, 15(Suppl 4):18395.

  Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study.
M May, M Gompels and C Sabin.
11th International Congress on Drug Therapy in HIV Infection, 2012. Oral O133.
Journal of the International AIDS Society 2012, 15(Suppl 4):18078.

  Recovery of dGFR in patients who develop renal complications on tenofovir.
S Jose, L Hamzah, L Campbell, C Sabin, F Post for the UK CHIC study.
11th International Congress on Drug Therapy in HIV Infection, 2012.
Journal of the International AIDS Society 2012, 15(Suppl 4):18137.

  Assessment of patient complexity using routinely collected data: The UK CHIC study.
C Sabin and V Delpech, for the UK Collaborative HIV Cohort (CHIC) Study.
11th International Congress on Drug Therapy in HIV Infection, 2012.
Journal of the International AIDS Society 2012, 15(Suppl 4):18133.


  Has a limit to the decline in transmitted drug resistance been reached? Evidence from a large surveillance study of UK-acquired infections.
D Dolling, C Sabin, V Delpech, E Smit, A Pozniak, I Williams, AM Geretti, N Mackie, D Pillay, D Dunn and UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.
19th Conference on Retroviruses and Opportunistic Infections, 2012. Abstract 732.

  2011

  Hepatitis B virus coinfection in HIV-infected patients in the UK Collaborative HIV Cohort (UK CHIC) study.
H Price, L Bansi, C Sabin and R Gilson.
17th Annual Conference of the British HIV Association (BHIVA), 2011. Oral O22.
HIV Medicine 2011; 12 (Suppl. 1), 1-13.

  Treatment outcomes in Black and Minority Ethnic (BME) and White men who have sex with men (MSM).
G Sethi, S Edwards, R Gilson and C Sabin.
17th Annual Conference of the British HIV Association (BHIVA), 2011. Poster P5.
HIV Medicine 2011; 12 (Suppl. 1), 14-86.

  Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI.
T Barber, L Harrison, D Asboe, I Williams, L Bansi, D Pillay and D Dunn.
17th Annual Conference of the British HIV Association (BHIVA), 2011. Poster P176.
HIV Medicine 2011; 12 (Suppl. 1), 14-86.

  Baseline renal function as predictor of mortality and renal disease progression in HIV-infected patients.
F Ibrahim, L Hamzah, R Jones, D Nitsch, C Sabin, F Post, and the UK CHIC/CKD Study Group.
18th Conference on Retroviruses and Opportunistic Infections, 2011.

  Differences in uptake of HIV care and cART between different ethnic MSM groups in the UK CHIC Study.
G Sethi, S Soni, B Redfern, R Gilson, S Edwards, C Sabin, for UK CHIC Study.
18th Conference on Retroviruses and Opportunistic Infections, 2011.

  2010

  Outcomes of second-line ritonavir-boosted protease inhibitor (PI/r)-based ART after failure of a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART.
L Waters, L Bansi, D Asboe, A Pozniak, C Orkin, E Smit and A Phillips.
16th Annual Conference of the British HIV Association (BHIVA), 2010. Oral O8.
HIV Medicine 2010; 11 (Suppl.1), 1-119.

  Baseline renal function is an independent predictor of death and progression to severe chronic kidney disease.
F Ibrahim, L Hamzah, R Jones, L Bansi, D Nitsch, C Sabin and F Post.
16th Annual Conference of the British HIV Association (BHIVA), 2010. Oral O26.
HIV Medicine 2010; 11 (Suppl.1), 1-119. Presentation
  Non-uptake of HAART among HIV-positive persns with a CD4 count <350 cells/mm3.
C Kober, MA Johnson, M Fisher, and C Sabin.
16th Annual Conference of the British HIV Association (BHIVA), 2010. Poster P5.
HIV Medicine 2010; 11 (Suppl. 1), 1-119. Presentation

  Use of antiretroviral therapy during and after pregnancy among HIV-infected women already aware of their infection before conceiving.
C Sabin, S Huntington, L Bansi, C Thorne and P Tookey.
16th Annual Conference of the British HIV Association (BHIVA), 2010. Poster P154.
HIV Medicine 2010; 11 (Suppl. 1), 1-119.

  Long-term probability of detecting HIV drug resistance in drug-naive patients starting currently recommended first-line combination ART.
A Cozzi-Lepri, D Dunn, D Pillay, C Sabin E Fearnhill, A Phillips, and UK HIV Drug Resistance Database and UK CHIC Study Groups.
17th Conference on Retroviruses and Opportunistic Infections, 2010.

  The frequency and clinical implications of a discordant CD4 count and CD4 percentage.
M Gompels, C Sabin, A Phillips, D Dunn and the UK Collaborative HIV Cohort (CHIC) Study.
17th Conference on Retroviruses and Opportunistic Infections, 2010.

  TB infections among HIV-infected Africans and Non-Africans in the UK.
A Grant, L Bansi, C Sabin, and the UK CHIC Study Group.
17th Conference on Retroviruses and Opportunistic Infections, 2010.

  Does cART with greater CNS penetration prevent the development of CNS opportunistic disease?
L Garvey, A Winston, C Sabin, and the UK CHIC Study Group.
17th Conference on Retroviruses and Opportunistic Infections, 2010. Presentation
  Cumulative risk of extensive triple-class virologic failure in 10,603 patients followed as long as 10 years from the start of ART.
A Phillips, A Wilson, C Leen, and the UK CHIC Study Group.
17th Conference on Retroviruses and Opportunistic Infections, 2010.

  Use of antiretroviral therapy during and after pregnancy among HIV-infected women already aware of their infection before conceiving.
S Huntington, L Bansi, C Thorne, P Tookey and C Sabin on behalf of the UK Collaborative HIV Cohort (CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC).
14th International Workshop on HIV Observational Databases, 2010. Poster 26.

  Comparison of MDRD and CKD-EPI to estimate renal function in HIV-infected patients.
F Ibrahim, F Post, and C Sabin on behalf of the UK CHIC/CKD study group.
14th International Workshop on HIV Observational Databases, 2010. Poster 104.

  Rate of virological failure and patterns of resistance for lamivudine/nevirapine combined with stavudine or zidovudine as first-line therapy: implications for resource-limited settings.
D Dunn, E Fearnhill, N Paton on behalf of the UK HIV Drug Resistance Database and UK CHIC.
14th International Workshop on HIV Observational Databases, 2010. Poster 123.

  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
L Harrison, H Castro (nee Green), P Cane, D Pillay, C Booth, A Phillips, AM Geretti, D Dunn on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study (UK CHIC).
International HIV & hepatitis Virus Drug Resistance Workshop & Curative Strategies, 2010. Abstract 41.

  2009

  Improving the quality of death data in the UK CHIC Study.
T Hill, T Hartney, T Chadborn, V Delpech and C Sabin.
15th Annual Conference of the British HIV Association, 2009. Abstract/Poster P109. Poster

  Factors influencing lopinavir (LPV) and atazanavir (ATV) plasma concentration.
W Stöhr, S Khoo, D Dunn, S Gibbons, T Hill, A Winston, C Sabin, D Back.
15th Annual Conference of the British HIV Association, 2009. Abstract/Poster 135.

  Clinical epidemiology of end-stage renal failure in the UK.
A Hughes, L Bansi, J Connolly, S Edwards, N Mackie, M Fisher, C Sabin and F Post.
15th Annual Conference of the British HIV Association, 2009. Abstract/Oral O5. Presentation

  Linkage of the UK Collaborative HIV cohort (CHIC) study and the National Study of HIV in Pregnancy and Childhood (NSHPC) to assess ART patterns in pregnant women.
L Bansi, C Thorne, P Tookey and C Sabin.
15th Annual Conference of the British HIV Association, 2009. Abstract/Poster P56.

  Late diagnosis in the HAART era: what do we mean by a late presenter?
C Sabin on behalf of the UK CHIC Study.
13th International Workshop on HIV Observational Databases, 2009. Abstract/Oral 1.

  Trends over calendar time in antiretroviarl treatment success and failure in HIV clinic populations.
L Bansi, C Sabin, V Delpech, A Phillips onn behalf of the UK CHIC Study.
13th International Workshop on HIV Observational Databases, 2009. Abstract/Oral 26.

  Positive and negative drug selection pressures on the N348I connection domain mutation; new insights from in vivo data.
H Price, D Dunn, D Asboe, A Pozniak, B Gazzard, D Pillay on behalf of the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort (CHIC) Study.
18th International HIV Drug Resistance Workshop, 2009.

  Detection of clinically relevant antiretroviral drug resistance mutations among treated patients undergoing testing at low levels of viraemia.
AM Geretti, AN PHillips, S Kaye, C Booth, NE Mackie on behalf the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort (CHIC) Study.
18th International HIV Drug Resistance Workshop, 2009. Poster.

  2008

  Viral rebound according to specific antiretrovirals in people who attain a viral load of less than 50 copies/ml.
C Smith, A Phillips, M Fisher for the UK Collaborative HIV Cohort (UK CHIC).
9th International Congress on Drug Therapy in HIV Infection, 2008. Abstract/Poster 604. Poster

  Do the disadvantages of late presentation of HAART persist in patients achieving and maintaining viral load (VL) suppression for a year on HAART?
LJ Waters, M Fisher, J Anderson, C Wood and CA Sabin.
9th International Congress on Drug Therapy in HIV Infection, 2008. Abstract/Oral O422.

  Trends in transmitted HIV drug resistance among non-B subtypes in the UK.
D Chilton, L Harrison, H Green, S Lattimore, V Delpech, D Pillay.
9th International Congress on Drug Therapy in HIV Infection, 2008. Abstract/Oral O112.

  The frequency and clinical implications of a discordant CD4 count and CD4 percentage.
M Gompels, C Sabin, A Phillips, D Dunn and the UK Collaborative HIV Cohort (CHIC) Study.
15th Conference on Retroviruses and Opportunistic Infections, 2008. Abstract 343. Poster

  Cumulative risk of extensive triple-class virologic failure in 10,603 patients followed as long as 10 years from the start of ART.
A Phillips, A Wilson, C Leen, and the UK CHIC Study Group.
15th Conference on Retroviruses and Opportunistic Infections, 2008. Abstract 532.

  Factors influencing efavirenz (EFV) and nevirapine (NVP) plasma concentration.
W Stöhr, S Khoo, D Dunn, S Gibbons, T Hill, A Winston, C Sabin, D Back.
14th Annual Conference of the British HIV Association, 2008. Abstract/Poster P145.

  Association between adverse events and mortlity: a validation analysis.
C Sabin, L Bansi, M Nelson, C Leen, UK CHIC Steering Committee.
14th Annual Conference of the British HIV Association, 2008. Abstract/Oral O12.

  Responses to HAART and clinical events in patients with a low CD4 count: late presenters versus late starters.
L J Waters, M J Fisher, J Anderson, C Wood, C Sabin for the UK CHIC Study Group.
14th Annual Conference of the British HIV Association, 2008. Abstract/Oral O30.

  Implications of post-HAART virological failure for trends in CD4 count - UK CHIC Study.
R Hughes, C Sabin, JAC Sterne.
12th International Workshop on HIV Observational Databases, 2008. Abstract/Poster 58.

  Factors influencing efavirenz and nevirapine plasma concentration.
W Stöhr, S Khoo, D Dunn, S Gibbons, T Hill, A Winston, C Sabin, D Back on behalf of the Liverpool TDM Database and the UK CHIC Study.
12th International Workshop on HIV Observational Databases, 2008. Abstract/Oral 27.

  Does the CD4 percentage provide additional prognostic information to the absolute CD4 count in the highly active antiretroviral therapy (HAART) era?
CA Sabin, DT Dunn, AN Phillips, M Gompels.
12th International Workshop on HIV Observational Databases, 2008. Abstract/Oral 20.

  Is one ALT >200 enough to be defined as an ALT flare: Differentiating between elevations and ALT flares.
L Bansi, J Turner, R Gilson, C Sabin.
12th International Workshop on HIV Observational Databases, 2008. Abstract/Oral 28.

 

Prevalence and patterns of antiretroviral drug resistance at low plasma HIV RNA load levels.
AM Geretti, A Phillips, S Kaye, C Booth, A Garcia, N Mackie on behalf of the UK HIV Drug Resistance Database and UK CHIC Study.
The 17th International HIV Drug Resistance Workshop, 2008. Poster.

  Effect of HIV-1 subtype on virological and immunological response to first -line HAART.
L Harrison, AM Geretti, H Green and D Dunn on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK CHIC Study.
14th British HIV Association (BHIVA) Annual Conference, 2008. Oral 10.

  The impact of resistance testing in ARV-naive patients: does it guide optimal therapy selection and improve long-term outcomes?
L Bansi, AM Geretti, D Dunn, C Sabin on behalf of the UK CHIC Study and UK Collaborative Group on HIV Drug Resistance.
14th British HIV Association (BHIVA) Annual Conference, 2008. Oral 8.

  Effect of HIV-1 subtype on virological and immunological response to first-line HAART.
AM Geretti, L Harrison, H Green, and D Dunn on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK CHIC Study.
6th European HIV Drug Resistance Workshop, 2008.

  Long-term probability of detecting HIV drug resistance in drug-naive patients starting currently recommended first-line combination ART.
A Cozzi-Lepri, D Dunn, D Pillay, C Sabin, E Fearnhill, A Phillips and UK HIV Drug Resistance Database and UK CHIC Study Groups.
15th Conference on Retroviruses and Opportunistic Infections (CROI), 2008.

  2007

  Association between resistance and CD4 count change in patients on ART with ongoing viraemia.
ZV Fox, AN Phillips for the UK Resistance Database, EuroSIDA and UK CHIC Studies.
11th International Workshop on HIV Observational Databases, 2007. Abstract/Poster 95.
.
  Reducing the impact of loss-to-follow-up in observational cohort studies.
L Bansi, T Hill, CA Sabin.
11th International Workshop on HIV Observational Databases, 2007. Abstract/Poster 66.

  Comparison of age/sex-specific all cause death rates in ART-naive patients with CD4 count >350 cells/mm3 compared with the general population: proposal for a joint analysis.
R Lodwick, AN Phillips for the UK CHIC Study.
11th International Workshop on HIV Observational databases, 2007. Abstract/Oral 20.

  Identifying toxicity-related treatment discontinuations (TRTD) in the absence of complete data on reasons for discontinuation.
CA Sabin, C Smith, AN Phillips, for the UK CHIC Study.
11th International Workshop on HIV Observational Databases, 2007. Abstract/Oral 16.

  Time trends in HIV drug resistnce in ART-experienced patients in the UK: impact of improved treatments and boosted protease inhibitors.
D Dunn, H Green, E Fearhill.
13th Annual Conference of the British HIV Association, 2007. Abstract/Oral O2
Ref: HIV Medicine, 8 (Suppl.1), 1-8.

  TB incidence among HIV-infected africans in the United Kingdom.
A Grant, L Bansi, C Sabin for the UK Collaborative HIV Cohort (UK CHIC).
14th Conference on Retroviruses and Opportunistic Infections, 2007. Presentation

  Long-term trends in CD4 counts in patients starting HAART: UK CHIC study.
R Hughes, C Sabin, JAC Sterne.
11th European AIDS Conference/EACS, 2007. Presentation

  Antiretroviral changes after viral load rebound in the UK Collaborative HIV Cohort (CHIC) study.
KJ Lee, DT Dunn, CA Sabin for the UK CHIC Study steering committee.
11th European AIDS Conference/EACS, 2007. Presentation

  Trends over calendar time in the prevalence of patients with extensive triple class virologic failure in the UK.
A Phillips, A Wilson, C Leen on behalf of UK CHIC.
13th Annual Conference of the British HIV Association, 2007. Presentation

  Epidemiology of non-B clade forms of HIV-1 in MSM in the UK.
J Fox, A Dudaz, H Green, D Dunn, S Kaye, M McClure and S Fidler on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK CHIC Study.
13th Annual Conference of the British HIV Association, 2007. Poster 117.

  2006

  HCV co-infection in the UK Collaborative HIV Cohort (UK CHIC) Study.
J Turner, L Bansi, RC Gilson, CA Sabin.
12th Annual Conference of the British HIV Association, 2006. Presentation

  The H208Y mutation in reverse transcriptase is significantly associated with NRTI exposure, M184V and TAM mutation pathways.
AM Geretti, C Sabin, D Dunn on behalf of the UK Collaborative Group on HIV drug Resistance and the UK Collaborative HIV Cohort (CHIC) Study Group.
15th International HIV Drug Resistance Workshop, 2006. Abstract 142.

  2005

  Immunological and clinical consequences of sustained low-level viremia in patients receiving HAART.
T Welz, L Bansi, P Easterbrook, C Sabin on behalf of the UK Collaborative HIV Cohort Study (CHIC).
3rd IAS Conference on HIV Pathogenesis and Treatment, 2005. Presentation
 
  Mutations at reverse transcriptase (RT) codons G196, Q207, H208, R211 and I214 are associated with drug experience and specific RT mutation patterns.
AM Geretti, C Sabin, D Dunn G Nebbia on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort (CHIC) Study Group.
14th International HIV Drug Resistance Workshop, 2005. Abstract 94.

  Predictors of death and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK.
D Grover, L Allen, SG Edwards, H Green, A Copas, S Forsyth and D Pillay on behalf of the UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study (UK CHIC).
14th International HIV Drug Resistance Workshop, 2005. Abstract 5.

  Virological and clinical outcomes in patients with multi (three)-class drug resistance (MDR).
D Grover, L Allen, D Pillay, H Green, A Copas, S Forsyth, SG Edwards on behalf of teh UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort study (UK CHIC).
11th Annual Conference of the British HIV Association, 2005.

  2004

  Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice.
AN Phillips, D Dunn, C Sabin, A Pozniak, R Matthias, AM Geretti, J Clarke, D Churchill, I Williams, T Hill, H Green, K Porter, G Scullard, M Johnson, P Easterbrook, R Gilson, M Fisher, C Loveday, B Gazzard and D Pillay on behalf of the UK HIV Drug Resistance Database and UK CHIC Groups.
13th International Drug Resistance Workshop, 2004. Poster 135.

  Estimating resistance in drug experienced patients in the UK.
D Pillay, H Green, B Gazzard, A Pozniak, R Matthias, M Johnson, D Churchill, M Fisher, T Hill, AM Geretti, J Clarke, P Cane, C Loveday, G Scullard, P Easterbrook, K Porter, I Williams, R Gilson, C Sabin, A Phillips and D Dunn on behalf of the UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study (UK CHIC).
13th International Drug Resistance Workshop, 2004. Poster 77.

  UK CHIC study presentation                                                                                      Back to top
  Click here to see a slide presentation describing the UK CHIC Study